Login to Your Account

AB Science Stock Surges as Masitinib Beats Sutent in GIST

By Cormac Sheridan
Staff Writer

Wednesday, February 8, 2012
Shares in AB Science SA surged 71.5 percent last week on news that its tyrosine kinase inhibitor masitinib strongly outperformed Sutent (sunitinib malate) in a Phase II head-to-head trial in 44 patients with Gleevec-resistant gastrointestinal stromal tumors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription